5-bromo APINACA
|
- $81 - $1260
- Product name: 5-bromo APINACA
- CAS: 2160555-51-9
- MF: C23H30BrN3O
- MW: 444.41
- EINECS:
- MDL Number:
- Synonyms:5-bromo APINACA;1H-Indazole-3-carboxamide, 1-(5-bromopentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-;1-(5-bromopentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
4 prices
Selected condition：
Brand
- AK Scientific
- Cayman Chemical
- TRC
Package
- 1mg
- 5mg
- ManufacturerAK Scientific
- Product number1523EN
- Product descriptionN-(1-Adamantyl)-1-(5-bromopentyl)indazole-3-carboxamide
- Packaging5mg
- Price$407
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number25209
- Product description5-bromo APINACA ≥98%
- Packaging1mg
- Price$81
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number25209
- Product description5-bromo APINACA ≥98%
- Packaging5mg
- Price$278
- Updated2024-03-01
- Buy
- ManufacturerTRC
- Product numberB679708
- Product description5-BromoAPINACA
- Packaging5mg
- Price$1260
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 1523EN | N-(1-Adamantyl)-1-(5-bromopentyl)indazole-3-carboxamide | 5mg | $407 | 2021-12-16 | Buy |
| Cayman Chemical | 25209 | 5-bromo APINACA ≥98% | 1mg | $81 | 2024-03-01 | Buy |
| Cayman Chemical | 25209 | 5-bromo APINACA ≥98% | 5mg | $278 | 2024-03-01 | Buy |
| TRC | B679708 | 5-BromoAPINACA | 5mg | $1260 | 2021-12-16 | Buy |
Properties
Boiling point :618.4±35.0 °C(Predicted)
Density :1.50±0.1 g/cm3(Predicted)
solubility :DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2)(1:8): 0.1 mg/ml; Ethanol: 10 mg/ml
form :A crystalline solid
pka :12.66±0.20(Predicted)
Density :1.50±0.1 g/cm3(Predicted)
solubility :DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2)(1:8): 0.1 mg/ml; Ethanol: 10 mg/ml
form :A crystalline solid
pka :12.66±0.20(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|